An asymmetric biotech opportunity

Vor Biopharma presents a compelling investment case, potentially worth over 4 times its current market value if its two main Phase 3 trials for Telitacicept succeed. The investment is significantly de-risked because the drug has already completed successful trials in China. Telitacicept targets a large addressable market with a strong efficacy profile, positioning it as a potential best-in-class treatment. The primary risk is the possibility of receiving a black box warning from regulators, which could limit its commercial potential.